VEGFA and malignant glioma: Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis and its selective inhibition by bevacizumab (Avastin), a humanized monoclonal antibody, has been reported to be beneficial as therapy for several types of cancers, including malignant gliomas [2, 3].